Trial · NCT01322048
DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury
NCT01322048, Phase 2, Completed, Vanderbilt University; results first posted 2017-06-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury. Trials, record NCT01322048. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01322048
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury
- NCT number
- NCT01322048
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 48 participants, actual
- Lead sponsor
- Vanderbilt University
- Conditions
- Brain Injuries, Craniocerebral Trauma, Trauma, Nervous System, Traumatic Brain Injury
- Interventions
- IV Propranolol and Per Tube Clonidine, Placebo
- First posted
- 2011-03-24
- Last updated
- 2017-08-17
- Results first posted
- 2017-06-08
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ventilator-free Days | Baseline to day 28 | |
| Secondary | Plasma Norepinephrine Levels | Post-treatment (t=Day 8) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Ventilator-free Days | Baseline to day 28 | days | MEDIAN | |
| SECONDARY | Plasma Norepinephrine Levels | Post-treatment (t=Day 8) | Of those surviving treatment period | pg/mL | MEDIAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ventilator-free Days | Adrenergic Blockade | 16.2 | Inter-Quartile Range 5.5 to 20.1 | days | |
| Ventilator-free Days | Placebo | 18.05 | Inter-Quartile Range 0.075 to 20.45 | days | |
| Plasma Norepinephrine Levels | Adrenergic Blockade | 962 | Inter-Quartile Range 508 to 1471 | pg/mL | |
| Plasma Norepinephrine Levels | Placebo | 714 | Inter-Quartile Range 391 to 1257 | pg/mL |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Adrenergic Blockade | 21 | |
| Overall Study | STARTED | Placebo | 26 | |
| Overall Study | COMPLETED | Adrenergic Blockade | 21 | |
| Overall Study | COMPLETED | Placebo | 26 | |
| Overall Study | NOT COMPLETED | Adrenergic Blockade | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adrenergic Blockade | 5 | 21 |
| Total, all-cause mortality | Placebo | 8 | 26 |
| Total, other adverse events | Adrenergic Blockade | 0 | 21 |
| Total, other adverse events | Placebo | 0 | 26 |
| Total, serious adverse events | Adrenergic Blockade | 0 | 21 |
| Total, serious adverse events | Placebo | 0 | 26 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Adrenergic Blockade vs Placebo: deaths from any cause | Trial comparisons |
| Adrenergic Blockade vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01322048
GET https://conductscience.org/api/trials/v1/NCT01322048/registered